Phase I/II study of human GM-CSF gene-transduced irradiated prostate allogeneic cancer cell vaccines (GVAX) in advanced prostate cancer patients made lymphopenic and infused with autologous peripheral blood mononuclear cells.

Trial Profile

Phase I/II study of human GM-CSF gene-transduced irradiated prostate allogeneic cancer cell vaccines (GVAX) in advanced prostate cancer patients made lymphopenic and infused with autologous peripheral blood mononuclear cells.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2009

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Apr 2008 Status changed from recruiting to completed according to a Cell Genesys media release.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top